Bristol Myers Squibb shares fell 2.4% to $61.47 after disclosure of a fatal septic pneumonia event following the data cutoff ...

Zai Lab reported an 81.8% response rate for zoci plus atezolizumab in a Phase 1b small cell lung cancer trial and plans a ...

Tango Therapeutics reported an 82% response rate with vopimetostat plus daraxonrasib in pancreatic cancer and plans a Phase 3 ...

Balchem reported Q3 2026 sales of $290.7 million, up 8.6%, while net earnings rose 16% to $46.7 million and adjusted EBITDA ...

GrafTech reported Q3 2026 sales of $140 million and a $47 million net loss, while planning a Monterrey facility closure ...

American Express Q3 2026 net income rose to $3.7 billion and EPS increased 31% to $5.42 as the company raised its full-year ...

Rithm Capital reported Q3 2026 net income of $217.1 million, distributable earnings of $315.3 million and a quarterly common ...

Rogers Communications Q3 2026 revenue rose 2% to C$5.443 billion, free cash flow increased 65%, and the company completed its ...

Zymeworks signs a Roche licensing deal worth up to $813 million for ZW209, including $55 million upfront and potential ...

Booz Allen Hamilton reported adjusted EPS of $1.76 in fiscal Q2 2027, beating estimates, while revenue reached $2.78 billion ...

IDEAYA reports a 60.8% response rate and 17.4-month median survival in second-line lung cancer patients treated with IDE849, ...

Apple Inc. has already shown there's a strong appetite for its $2,000-and-up foldable iPhone Duo. Now it needs to meet that ...